{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Korarchaeota : Questions médicales les plus fréquentes",
"headline": "Korarchaeota : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Korarchaeota : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-04",
"dateModified": "2025-04-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Korarchaeota"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Archéobactéries",
"url": "https://questionsmedicales.fr/mesh/D001105",
"about": {
"@type": "MedicalCondition",
"name": "Archéobactéries",
"code": {
"@type": "MedicalCode",
"code": "D001105",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B02"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Korarchaeota",
"alternateName": "Korarchaeota",
"code": {
"@type": "MedicalCode",
"code": "D019708",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Luke J McKay",
"url": "https://questionsmedicales.fr/author/Luke%20J%20McKay",
"affiliation": {
"@type": "Organization",
"name": "Department of Land Resources and Environmental Sciences, Montana State University, Bozeman, MT, USA. luke.mckay@montana.edu."
}
},
{
"@type": "Person",
"name": "Mensur Dlakić",
"url": "https://questionsmedicales.fr/author/Mensur%20Dlaki%C4%87",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, Montana State University, Bozeman, MT, USA."
}
},
{
"@type": "Person",
"name": "Matthew W Fields",
"url": "https://questionsmedicales.fr/author/Matthew%20W%20Fields",
"affiliation": {
"@type": "Organization",
"name": "Center for Biofilm Engineering, Montana State University, Bozeman, MT, USA."
}
},
{
"@type": "Person",
"name": "Tom O Delmont",
"url": "https://questionsmedicales.fr/author/Tom%20O%20Delmont",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, University of Chicago, Chicago, IL, USA."
}
},
{
"@type": "Person",
"name": "A Murat Eren",
"url": "https://questionsmedicales.fr/author/A%20Murat%20Eren",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, University of Chicago, Chicago, IL, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.",
"datePublished": "2024-01-25",
"url": "https://questionsmedicales.fr/article/38270329",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ppul.26861"
}
},
{
"@type": "ScholarlyArticle",
"name": "Promoting early childhood oral health and preventing early childhood caries on Instagram.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36686599",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/froh.2022.1062421"
}
},
{
"@type": "ScholarlyArticle",
"name": "Machine learning-derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor-immune interaction mechanisms.",
"datePublished": "2024-10-16",
"url": "https://questionsmedicales.fr/article/39415336",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/biof.2129"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.",
"datePublished": "2024-09-12",
"url": "https://questionsmedicales.fr/article/39329126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fphar.2024.1438288"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oncological outcomes after laparotomic, laparoscopic, and robot-assisted laparoscopic staging for early high-intermediate or high-risk endometrial cancer.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39019491",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/ijgc-2024-005510"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Archéobactéries",
"item": "https://questionsmedicales.fr/mesh/D001105"
},
{
"@type": "ListItem",
"position": 3,
"name": "Korarchaeota",
"item": "https://questionsmedicales.fr/mesh/D019708"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Korarchaeota - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Korarchaeota",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Korarchaeota",
"description": "Comment identifier les Korarchaeota dans un échantillon ?\nQuels tests sont utilisés pour détecter les Korarchaeota ?\nLes Korarchaeota peuvent-elles être cultivées en laboratoire ?\nQuels milieux favorisent la croissance des Korarchaeota ?\nY a-t-il des marqueurs spécifiques pour les Korarchaeota ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Korarchaeota",
"description": "Quels symptômes sont associés aux infections par Korarchaeota ?\nLes Korarchaeota provoquent-elles des maladies humaines ?\nPeut-on observer des symptômes chez d'autres organismes ?\nLes Korarchaeota sont-elles liées à des maladies ?\nComment les Korarchaeota affectent-elles leur environnement ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Korarchaeota",
"description": "Comment prévenir les infections par Korarchaeota ?\nLes Korarchaeota sont-elles dangereuses pour l'homme ?\nComment éviter la contamination par des archées ?\nLes Korarchaeota peuvent-elles affecter la santé des écosystèmes ?\nY a-t-il des mesures de sécurité en laboratoire ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Korarchaeota",
"description": "Y a-t-il des traitements pour les infections par Korarchaeota ?\nComment les Korarchaeota sont-elles utilisées en biotechnologie ?\nLes Korarchaeota peuvent-elles être utilisées en médecine ?\nQuels avantages les Korarchaeota offrent-elles en recherche ?\nPeut-on exploiter les Korarchaeota pour des biocarburants ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Korarchaeota",
"description": "Quelles complications peuvent survenir avec les Korarchaeota ?\nLes Korarchaeota peuvent-elles causer des déséquilibres écologiques ?\nY a-t-il des risques liés à l'étude des Korarchaeota ?\nLes Korarchaeota peuvent-elles interagir avec d'autres micro-organismes ?\nLes Korarchaeota sont-elles résistantes aux antibiotiques ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Korarchaeota",
"description": "Quels facteurs favorisent la présence des Korarchaeota ?\nLes Korarchaeota sont-elles sensibles aux changements environnementaux ?\nQuels habitats sont propices aux Korarchaeota ?\nLes Korarchaeota sont-elles affectées par la pollution ?\nY a-t-il des conditions spécifiques pour les Korarchaeota ?",
"url": "https://questionsmedicales.fr/mesh/D019708?mesh_terms=Early+Detection+of+Cancer&page=999#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les Korarchaeota dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par séquençage de l'ADN et techniques de culture spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les Korarchaeota ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et des analyses phylogénétiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota peuvent-elles être cultivées en laboratoire ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont difficiles à cultiver, nécessitant des conditions spécifiques de chaleur et de pH."
}
},
{
"@type": "Question",
"name": "Quels milieux favorisent la croissance des Korarchaeota ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles prospèrent dans des milieux riches en chaleur, comme les sources hydrothermales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour les Korarchaeota ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des gènes spécifiques, comme ceux de la méthanogenèse, peuvent servir de marqueurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux infections par Korarchaeota ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les Korarchaeota ne sont pas pathogènes pour l'homme, donc pas de symptômes associés."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota provoquent-elles des maladies humaines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont principalement étudiées dans des contextes environnementaux et non pathogènes."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes chez d'autres organismes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent influencer des écosystèmes, mais ne causent pas de symptômes directs."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota sont-elles liées à des maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, aucune association avec des maladies humaines n'est établie."
}
},
{
"@type": "Question",
"name": "Comment les Korarchaeota affectent-elles leur environnement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles jouent un rôle dans le cycle des nutriments et la décomposition dans les milieux extrêmes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections par Korarchaeota ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune prévention n'est nécessaire, car elles ne causent pas d'infections chez l'homme."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota sont-elles dangereuses pour l'homme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne sont pas considérées comme dangereuses ou pathogènes pour l'homme."
}
},
{
"@type": "Question",
"name": "Comment éviter la contamination par des archées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les environnements extrêmes où elles prospèrent, comme les sources chaudes."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota peuvent-elles affecter la santé des écosystèmes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles jouent un rôle crucial dans les écosystèmes extrêmes, mais ne nuisent pas à la santé humaine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures de sécurité en laboratoire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des protocoles de sécurité standard sont appliqués lors de la manipulation d'archées en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements pour les infections par Korarchaeota ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucun traitement n'est nécessaire, car elles ne sont pas pathogènes pour l'homme."
}
},
{
"@type": "Question",
"name": "Comment les Korarchaeota sont-elles utilisées en biotechnologie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont étudiées pour leurs enzymes thermophiles, utiles dans divers processus industriels."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota peuvent-elles être utilisées en médecine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne sont pas utilisées en médecine, mais leur étude peut inspirer des innovations."
}
},
{
"@type": "Question",
"name": "Quels avantages les Korarchaeota offrent-elles en recherche ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à comprendre l'évolution des archées et leur rôle dans les écosystèmes extrêmes."
}
},
{
"@type": "Question",
"name": "Peut-on exploiter les Korarchaeota pour des biocarburants ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont étudiées pour leur potentiel dans la production de biocarburants à partir de biomasse."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les Korarchaeota ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune complication n'est associée aux Korarchaeota, car elles ne sont pas pathogènes."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota peuvent-elles causer des déséquilibres écologiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent influencer les écosystèmes, mais ne causent pas de déséquilibres notables."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés à l'étude des Korarchaeota ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques sont minimes, mais des précautions doivent être prises lors de la manipulation."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota peuvent-elles interagir avec d'autres micro-organismes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent interagir avec d'autres archées et bactéries dans leur habitat."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota sont-elles résistantes aux antibiotiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne sont pas testées pour la résistance aux antibiotiques, car elles ne sont pas pathogènes."
}
},
{
"@type": "Question",
"name": "Quels facteurs favorisent la présence des Korarchaeota ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles se trouvent dans des environnements extrêmes, comme les sources chaudes et les geysers."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota sont-elles sensibles aux changements environnementaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont adaptées aux conditions extrêmes, mais peuvent être affectées par des changements rapides."
}
},
{
"@type": "Question",
"name": "Quels habitats sont propices aux Korarchaeota ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les habitats géothermiques, comme les sources chaudes, sont idéaux pour leur croissance."
}
},
{
"@type": "Question",
"name": "Les Korarchaeota sont-elles affectées par la pollution ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être sensibles à la pollution, mais prospèrent généralement dans des milieux extrêmes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conditions spécifiques pour les Korarchaeota ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles nécessitent des températures élevées et des niveaux de pH spécifiques pour croître."
}
}
]
}
]
}
Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years...
Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a...
Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI...
In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...
Early childhood caries (ECC) is prevalent worldwide. Oral health promotion effectively utilizes key messages to educate parents/caregivers and the public on how to prevent ECC. Instagram is one of the...
This study used inductive content analysis to categorize, quantify, and interpret pictorial and textual data derived from Instagram posts containing the most commonly used ECC-related hashtags in thei...
A total of 1,071 images and 3,228 comments were analyzed based on 13 hashtags. The most common types of images were those of people (57.5%) and graphics/memes (37.8%). Most people were older children ...
As more people engage with social media, health professionals should consider the potential for Instagram as a tool to promote early childhood oral health and to prevent ECC. Our study shows that many...
Lung cancer continues to be the leading cause of cancer-related mortality worldwide. Early detection and a comprehensive understanding of tumor-immune interactions are crucial for improving patient ou...
The combination of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors and endocrine therapy is the standard treatment for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced bre...
This study aimed to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in patients with HR+, HER2- early breast cancer. A systematic r...
Eight randomized controlled trials (RCTs) were included in the study. CDK4/6 inhibitors combined with endocrine therapy showed a significant improvement in IDFS (hazard ratio (HR) = 0.81, 95% confiden...
The addition of CDK4/6 inhibitors in HR+/HER2- early breast cancer patients significantly improved IDFS in adjuvant therapy and CCCA in neoadjuvant. However, CDK4/6 inhibitors also showed significant ...
Identifier CRD42024530704....
To compare oncological outcomes in patients with early-stage high-intermediate or high-risk endometrial cancer undergoing surgical staging by laparotomy, conventional laparoscopy, or robot-assisted la...
Patients diagnosed between 2015 and 2021 with stage I-II (International Federation of Gynecology and Obstetrics 2009), high-intermediate or high-risk endometrial cancer who underwent staging surgery, ...
In total 941 patients met the inclusion criteria, of whom 399 (42.4%) underwent staging surgery by laparotomy, 273 (29.0%) by laparoscopy, and 269 (28.6%) by robot-assisted laparoscopy. Baseline chara...
Laparoscopic and robot-assisted laparoscopic staging surgery in women with early-stage high-intermediate or high-risk endometrial cancer are safe alternatives to laparotomic staging surgery....
Childhood, teenage and young adult (CTYA, 0-24 years) cancers are rare and diverse, making timely diagnosis challenging. We aim to explore symptoms and symptom combinations associated with a subsequen...
Using the QResearch Database, we carried out a matched nested case-control study. Associations between pre-specified symptoms encountered in primary care and a subsequent diagnosis of any cancer were ...
3186 cases and 50,576 controls were identified from a cohort of 3,424,771 CTYA. We identified 12 novel associations, of which hemiparesis [OR 90.9 (95%CI 24.7-335.1), PPV = 1.6%], testicular swelling ...
Using the largest cohort to date, we provide novel information on the time-varying predictive utility of symptoms in the diagnosis of CTYA cancers. Our findings will help to raise clinical and public ...
Approximately 20% of patients with colorectal cancer (CRC) are diagnosed with a mucinous subtype of this tumor, have a worse prognosis, and often show resistance to available therapies. Molecules from...
Breast cancer radiotherapy can increase the risks of heart disease, lung cancer and oesophageal cancer. At present, the best dosimetric predictors of these risks are mean doses to the whole heart, lun...
A systematic review and meta-analysis was conducted of planned or delivered mean doses to the whole heart, lungs or oesophagus from UK breast cancer radiotherapy in studies published during 2015-2023....
For whole heart, thirteen studies reported 2893 doses. Average mean doses were higher in left than in right-sided radiotherapy and increased with extent of clinical targets. For left-sided radiotherap...
The typical doses to these organs may be combined with dose-response relationships to estimate radiation risks. Estimated 30-year absolute lung cancer mortality risks from modern UK breast cancer radi...
We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast cancer and evaluated the predictive valu...
We prospectively enrolled 208 plasma samples collected at three time points (before PST, after 2 cycles of treatment, before surgery) of 72 patients with stage Ⅱ-III breast cancer. Somatic mutations i...
37 of 72 (51.4%) patients harbored detectable ctDNA alterations at baseline. Patients with complete response showed a larger decrease in ctDNA levels during PST. The median relative change of variant ...
Early changes of ctDNA are strongly correlated with therapeutic efficacy to PST and clinical outcomes in BC patients. The integration of preoperative ctDNA evaluation could help improving the perioper...
Human papillomavirus-associated (HPV+) head and neck squamous cell carcinoma (HNSCC) is the most common HPV-associated cancer in the United States, with a rapid increase in incidence over the last two...